Symptomatic MAPT mutation carriers scored much lower at baseline than the other MAPT mutation carriers, a result that is consistent with findings from other cross-sectional [5, 15–17] and longitudinal [18] familial FTD studies. This evidence concerns the gene MAPT and frontotemporal dementia.